evipedia.ai
← Back

GlyNAC for Health & Longevity

Evidence Review created on 09/12/2026 using AI4L / Opus 5

Also known as: Gly-NAC, Glycine & N-Acetylcysteine, Glycine, N-Acetylcysteine, N-Acetyl-L-Cysteine, Acetylcysteine, NAC

Motivation

GlyNAC is a pairing of two inexpensive amino acids — glycine and N-acetylcysteine — taken together as an oral supplement. Both are building blocks of glutathione, the most abundant antioxidant made inside human cells, and the amount of it that cells hold falls with advancing age. The idea behind the pairing is simple: supply the two raw materials that grow scarce, and the body may rebuild its own defences rather than receive an antioxidant from outside.

Each ingredient has a long separate history. N-acetylcysteine has been used in hospitals for decades to thin mucus and as the standard treatment for acetaminophen overdose, while glycine is an ordinary dietary amino acid, abundant in collagen and gelatin. Interest in giving them together grew from work at one academic centre reporting that older adults who took both showed movement in several measures of aging biology and physical capacity, and from mouse work reporting a longer life.

This review examines what the published human and animal evidence actually shows, where that evidence is firm, thin, or contradictory, how the compounds are dosed and monitored, and what drawbacks accompany them.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of GlyNAC from expert platforms and narrative scientific literature.

No relevant content was found on peterattiamd.com, hubermanlab.com or chriskresser.com by either web search or on-site search, so those platforms are not represented; five qualifying items were nonetheless available.

Grokipedia

  • GlyNAC

    A fact-checked encyclopedia entry covering composition, glutathione biochemistry, the Baylor trial record with its sample-size limits, dosing and drawbacks, with each claim tied to a numbered primary source.

Examine

  • GlyNAC

    Examine’s dedicated, independently fact-checked page: it states plainly that the GlyNAC evidence base is small, names the conditions where signal exists, and gives the exact dosing used in trials.

ConsumerLab

  • NAC (N-Acetyl Cysteine) Supplements Review

    ConsumerLab publishes no standalone GlyNAC review; this NAC review carries its GlyNAC comparison and its independent purity and label-accuracy testing of the N-acetylcysteine half of the pair.

Systematic Reviews

This section lists the systematic reviews and meta-analyses closest to GlyNAC’s claimed benefits and its principal risk.

Both sides of the trade-off are represented, but only for single agents: no systematic review or meta-analysis covers GlyNAC itself, for either benefit or harm.

Mechanism of Action

Glutathione is a three-part molecule assembled from glutamate, cysteine and glycine. Cells build it in two energy-requiring steps: glutamate-cysteine ligase (the rate-limiting enzyme) joins glutamate to cysteine, then glutathione synthetase attaches glycine. Both cysteine and glycine supply decline in older adults, so either can throttle the pathway. N-acetylcysteine is a stable, absorbable carrier of cysteine — free cysteine is unstable and poorly tolerated — and is deacetylated in gut and liver to release it; glycine supplies the second substrate. The stated reason for giving them together is additive: relieving one shortage alone leaves the other binding, and the founding human study supplied both.

Pharmacologically, oral N-acetylcysteine is poorly bioavailable (about 4–10%), has a terminal half-life near 6 hours, a distribution volume around 0.5 L/kg, roughly 50% protein binding, and mainly non-renal clearance; it is not a meaningful substrate or inhibitor of cytochrome P450 (the liver’s main drug-metabolising enzyme family), and its chief excretory product is inorganic sulfate (Holdiness, 1991). Glycine is absorbed rapidly, cleared within hours, and consumed by collagen, creatine, heme, bile-salt and detoxification-conjugation pathways; it is also a co-agonist at N-methyl-D-aspartate receptors (a brain glutamate receptor).

Restored glutathione is proposed to lower reactive oxygen species (unstable oxygen molecules that damage cells) and normalise the cell signalling those molecules control. The competing mechanistic reading is that those same species are necessary signals: suppressing them can blunt adaptation, and precursor supply may not be limiting at all in healthy older adults.

Historical Context & Evolution

N-acetylcysteine entered medicine in the 1960s as an inhaled mucolytic (a mucus thinner) for chronic bronchitis, then became the standard antidote for acetaminophen poisoning in the 1970s, a use for which it sits on the World Health Organization’s essential medicines list. Glycine took a different route: an ordinary dietary amino acid, it was studied as a sleep aid, as an add-on in schizophrenia, and as a protectant against tissue injury after blood-flow interruption.

The two converged in 2011, when a Baylor College of Medicine group reported that older adults had markedly lower red-cell glutathione than young adults because synthesis was limited by low glycine and cysteine, and that two weeks of both precursors restored it (Sekhar et al., 2011). That finding — a measured synthesis defect with an identified cause, not an assumption — drove everything after it: open-label trials in people with HIV (human immunodeficiency virus) and in older adults, a mouse lifespan experiment, a pilot in type 2 diabetes, and a placebo-controlled trial.

Nearly all of that work comes from one laboratory, whose authors declare no financial conflicts. The single independent randomized trial was designed and funded by Nestlé Health Science, which markets a glycine and N-acetylcysteine product, and it did not reproduce the glutathione rise. Both bodies of evidence carry a structural interest; neither has been retracted or refuted, and the disagreement remains open.

Expected Benefits

High 🟩 🟩 🟩

Improved Physical Function and Muscle Strength in Older Adults

Gait speed and handgrip strength improved on GlyNAC in a 16-week placebo-controlled randomized controlled trial (RCT — a study in which participants are allocated by chance to treatment or a placebo) in 24 older adults using an alanine placebo, where 6-minute walk distance only trended upward. Walk distance did rise in a 24-week open-label pilot and an open-label trial in people with HIV. All three tested the combination, not a single agent, and all three come from one laboratory, with small samples and no independent replication.

Magnitude: In the placebo-controlled trial, gait speed rose from 1.13 to 1.34 m/s and dominant-hand grip strength from 32.3 to 36.7 kg over 16 weeks, while 6-minute walk distance moved from 523 to 565 m without reaching significance; the placebo arm changed on none of the three. Gains in the open-label pilot receded within 12 weeks of stopping.

Fewer and Milder Respiratory Infections

Six months of N-acetylcysteine cut the frequency and severity of influenza-like episodes, and the days spent confined to bed, in a 262-person randomized trial of mostly older adults, and a meta-analysis of twenty trials found fewer airway exacerbations in chronic bronchitis and chronic obstructive pulmonary disease (long-term airflow obstruction). N-acetylcysteine alone, not the combination, at 1.2 g daily — under a seventh of the GlyNAC dose. Participants were elderly or already had airway disease, so transfer to healthy adults is untested.

Magnitude: Among participants infected with influenza A virus, 25% of those on N-acetylcysteine developed symptomatic illness against 79% on placebo. Pooled exacerbation incidence fell roughly a quarter in chronic obstructive pulmonary disease and a fifth in chronic bronchitis.

Medium 🟩 🟩

Lower Systolic Blood Pressure

Older adults entered the placebo-controlled trial with higher systolic blood pressure than young comparators, and 16 weeks of GlyNAC — not the alanine placebo — moved it toward the young-adult range. Blood pressure is a surrogate with established links to cardiovascular events, which is why this sits above the biomarker items. The trial tested the combination. It is one trial of 24 people; the report does not isolate how much of the change is attributable to glycine’s known vascular effects.

Magnitude: Systolic pressure fell from 132.0 to 124.4 mmHg over 16 weeks on GlyNAC — about 8 mmHg — and was unchanged on placebo. The fall applies only to participants who began above the young-adult reference of roughly 111 mmHg.

Low 🟩

Lower Insulin Resistance and Improved Mitochondrial Fuel Handling

Fasting insulin and insulin resistance fell, and the balance between fat and glucose burning in mitochondria (the cell’s energy compartments) shifted toward the young-adult pattern. Shown in a 14-day pilot in type 2 diabetes and the 24-week open-label pilot; both tested the combination, neither had a placebo arm.

Magnitude: In 10 adults with type 2 diabetes, 14 days lowered insulin resistance 22%, raised mitochondrial fat oxidation 30%, lowered mitochondrial glucose oxidation 47% and free fatty acids 25%. In 8 older adults over 24 weeks, fasting insulin fell 55%, insulin resistance 59% and fasting glucose 9%.

Improved Cognitive Test Performance

Scores rose on the Montreal Cognitive Assessment, trail-making, verbal fluency and digit-symbol substitution tests after 24 weeks, and fell again after stopping — an argument against simple practice effects. Both trials showing this tested the combination, and both were open-label without a placebo arm.

Magnitude: Direction only: every cognitive test administered improved during supplementation and several declined 12 weeks after withdrawal (Kumar et al., 2021). The uncontrolled design means no effect-size figure can be attributed to the supplement.

Reduced Body Fat and Waist Circumference

Central fat fell modestly alongside the shift back toward fat burning. Evidence is the single 24-week open-label pilot of the combination, with no placebo arm and no independent replication.

Magnitude: Fat mass fell 4% and waist circumference 4 cm over 24 weeks in 8 older adults (Kumar et al., 2021), with the changes beginning to reverse after withdrawal.

Lower Inflammatory and Vessel-Activation Markers ⚠️ Conflicted

Interleukin-6 (an inflammatory signalling protein), tumour necrosis factor-alpha, C-reactive protein and markers of blood-vessel-lining activation all fell in the open-label combination pilot, but pooled controlled evidence for N-acetylcysteine alone found no effect on C-reactive protein. Net reading: the uncontrolled combination data overstate what controlled single-agent evidence supports.

Magnitude: In 8 older adults, interleukin-6 fell 77%, tumour necrosis factor-alpha 57% and C-reactive protein 49% (Kumar et al., 2021); the pooled N-acetylcysteine meta-analysis found C-reactive protein unchanged (standardised mean difference — the pooled effect in standard-deviation units — −0.1, with a 95% confidence interval, the range the true value most likely occupies, of −0.52 to 0.32).

Reported in adults with HIV, who carry a glutathione deficit comparable to that of much older people, after a short course of the combination. Open-label and population-specific, so it transfers to healthy older adults only by analogy.

Magnitude: Direction only: fatigue perception fell and quality-of-life scores rose within weeks of starting (Sekhar, 2021). The report is a short open-label communication and gives no controlled effect size.

Faster Sleep Onset and Better Sleep Quality from Glycine

Glycine taken before bed shortens time to sleep and improves subjective sleep quality, by lowering core temperature through skin blood flow. Glycine alone, not the combination. A systematic review of 52 human studies found sleep among glycine’s strongest signals, though those trials are small and at high risk of bias.

Magnitude: Direction only, conditional on timing and dose: sleep-onset latency falls and subjective sleep quality rises at roughly 3 g of glycine before bed (Bannai & Kawai, 2012). No trial has measured sleep at the much larger split doses used for GlyNAC, and the literature reports no pooled effect size.

Speculative 🟨

Restored Intracellular Glutathione and Lower Oxidative-Damage Markers ⚠️ Conflicted

Baylor trials of the combination report red-cell glutathione roughly tripling and oxidative-damage markers falling by three-quarters; an independent 114-person trial missed its glutathione endpoint. Net reading: the rise appears real only where demand is high.

Extended Lifespan

Basis is animal only: mice given the combination from mid-life lived 24% longer than controls, 129 versus 104 weeks, in both sexes. No human lifespan or mortality data exist.

Reversal of Genomic-Damage and Nutrient-Sensing Aging Hallmarks

Basis is unvalidated biomarkers plus animal work: a genetic-damage marker fell 66% in the open-label combination pilot, and mouse tissue showed restored mitophagy (clearance of worn-out mitochondria) and nutrient sensing. No human outcome exists.

Benefit-Modifying Factors

  • Baseline glutathione and oxidative-stress status: The strongest modifier. In the independent 114-person trial the primary endpoint was missed overall, yet participants in the top half for oxidative damage and bottom half for glutathione did generate more glutathione on the higher doses.

  • Chronological age: Young adults given the combination for two weeks showed little to correct; the entire benefit signal comes from people over 60, or from younger people carrying a disease that mimics that deficit.

  • Pre-existing metabolic disease: Type 2 diabetes and HIV both lower glycine and cysteine availability and both produced larger measured shifts than healthy aging did, implying that the further below normal a person starts, the more room there is to move.

  • Sex: Mouse lifespan gains were equal in males and females, but a rodent study of glutathione-precursor feeding found sex-divergent cardiac responses. No human trial has been powered to test sex differences in benefit.

  • Genetic variation in glutathione handling: Null variants of the glutathione S-transferase genes GSTM1 and GSTT1 (enzymes that attach glutathione to toxins) and reduced-function variants of the rate-limiting synthesis enzyme plausibly shift how much benefit precursor loading delivers. This is untested in any GlyNAC trial.

  • Dietary protein and glycine intake: People already eating collagen-rich or gelatin-rich diets carry a smaller glycine gap, so the glycine half of the pair has less to add.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Intolerance from N-Acetylcysteine

Nausea, vomiting and diarrhoea are the most frequently reported reactions to acetylcysteine and are documented across its clinical use and in a systematic review of its adverse reactions. This is established for N-acetylcysteine alone; the co-administration adds a burden of its own, because the trial dose for a 70 kg adult is roughly 16 g of combined powder daily, far more material than either agent is normally taken in. Reactions are dose-related and resolve on stopping.

Magnitude: Direction is consistent and dose-dependent, with complaints clustering at gram-level daily intakes rather than the few hundred milligrams used in older mucolytic regimens; the systematic review reports oral frequency at least as high as intravenous but publishes no single pooled incidence figure.

Medium 🟥 🟥

Blunted Muscle Recovery and Training Adaptation ⚠️ Conflicted

Thiol (sulfur-bearing) antioxidants raise muscle glutathione but interrupt the reactive-oxygen signalling that drives repair and growth after training. In a crossover randomized trial of 10 men given N-acetylcysteine at 20 mg/kg daily after eccentric (muscle-lengthening) exercise, growth-pathway phosphorylation was suppressed and only the placebo arm regained full performance. Against that, a pooled analysis of twenty trials found soreness, lactate and oxidative damage lower after exertion. Both tested N-acetylcysteine alone, at a seventh of the GlyNAC dose. Net reading: soreness eases while the adaptive signal converting training into strength is damped.

Magnitude: Muscle performance returned fully to baseline over eight days of recovery only in the placebo arm; on N-acetylcysteine the early drop in strength was blunted, yet the rise in growth-signalling phosphorylation at two and eight days was attenuated and full recovery never arrived. The literature reports no outcome figure for the size of the adaptive loss.

Low 🟥

Anaphylactoid Reactions to N-Acetylcysteine

Rash, itching, angioedema (deep tissue swelling), bronchospasm (sudden airway narrowing) and rarely low blood pressure occur with acetylcysteine through a histamine-mediated, non-immune route. Documented mainly with intravenous dosing in overdose settings, so its transfer to oral supplement use is indirect. N-acetylcysteine alone.

Magnitude: Direction and susceptibility are established rather than quantified: women and people with asthma or atopy (a general tendency to allergic reactions) are disproportionately affected, and reactions cluster at treatment onset when concentrations peak (Sandilands & Bateman, 2009).

Daytime Drowsiness and Lowered Core Body Temperature from Glycine

Glycine before bed shortens time to sleep and lowers core temperature by promoting skin blood flow, an effect traced to receptors in the brain’s master clock. Useful at night, unhelpful if a large dose lands in the morning. Human data are small and uncontrolled. Glycine alone.

Magnitude: Direction only, conditional on timing: sedative and temperature-lowering effects appear at roughly 3 g taken before bed (Bannai & Kawai, 2012). No trial has quantified daytime drowsiness at the much larger split doses used for GlyNAC.

Amino-Acid and Nitrogen Load in Impaired Kidney or Liver Function

Every GlyNAC trial excluded creatinine above 1.5 mg/dL and transaminases (enzymes released by stressed liver cells) above twice normal, so the supplement has never been tested where nitrogen handling is compromised. The risk is inferred from that exclusion, not observed. Applies to the combination as given.

Magnitude: Direction only: no signal has been observed within the tested range, where four-weekly creatinine and transaminase monitoring stayed normal throughout 24 weeks (Kumar et al., 2021). Above that range there are no data at all.

Speculative 🟨

Acceleration of Existing Tumour Growth

Basis is animal only: N-acetylcysteine accelerated lung cancer progression and increased melanoma metastasis in mice carrying established tumours, by relieving oxidative restraint on cancer cells. No human counterpart exists.

Long-Term Suppression of Beneficial Oxidative Signalling

Basis is mechanistic and concerns the combination: sustained antioxidant tone could dampen the brief oxidative bursts driving stress adaptation, immune killing and mitochondrial renewal. No human trial has run long enough to test it.

Risk-Modifying Factors

  • Asthma and atopy: Both raise susceptibility to acetylcysteine’s histamine-mediated reactions, including bronchospasm; a history of either shifts the risk calculation more than any other single factor.

  • Reduced kidney or liver function: Creatinine above 1.5 mg/dL or transaminases above twice normal were universal trial exclusions, leaving the nitrogen and sulfate load of a 16 g daily dose untested in these groups.

  • Sex: Women are over-represented among those reacting to acetylcysteine. In aged mice, the combination helped males but left females with worse exercise performance. No human data either way.

  • Baseline blood pressure: Already-low or medication-controlled blood pressure narrows the margin, since the combination lowered systolic pressure in the only placebo-controlled trial.

  • Active malignancy: The mouse tumour-progression findings make an established, untreated cancer the clearest reason to treat the risk side as unresolved rather than reassuring.

  • Older age with polypharmacy: More concurrent medication means more chance of the thiol group interacting, and older kidneys clear the added load more slowly.

  • Glutathione-handling gene variants: Variants in GSTM1, GSTT1 and in GCLM (a gene setting how fast glutathione’s first synthesis step runs) change how quickly supplied precursors are consumed, plausibly shifting both benefit and sulfur-compound accumulation.

Key Interactions & Contraindications

  • Organic nitrates for angina (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate): Caution. The thiol group regenerates nitrate responsiveness, so vessel widening is amplified — severe headache and faintness. Mitigation: separation of dosing by four hours, with seated and standing blood-pressure checks.

  • Blood-pressure medicines (angiotensin-converting enzyme inhibitors such as lisinopril, angiotensin-receptor blockers such as losartan, thiazides such as hydrochlorothiazide, calcium-channel blockers such as amlodipine): Caution. Additive lowering, since GlyNAC itself lowered systolic pressure. Mitigation: home blood-pressure logging for four weeks after starting, with prescriber-led dose review.

  • Carbamazepine (a prescription seizure medicine): Caution. N-acetylcysteine has been reported to lower circulating carbamazepine, risking loss of seizure control. Mitigation: drug-level measurement before and four weeks after starting, with prescriber supervision throughout.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution. Acetylcysteine reduces clotting-factor activity and prolongs clotting times, adding to bleeding risk. Mitigation: clotting-time testing (international normalised ratio) before and four weeks after starting, with prescriber supervision.

  • Clozapine and other antipsychotics (risperidone, haloperidol): Caution. High-dose glycine added nothing to clozapine in a placebo-controlled trial and may work against it at the same receptor. Mitigation: avoidance of the pairing, or close tracking of symptom scores.

  • Activated charcoal (over-the-counter): Caution. Charcoal adsorbs up to 96% of an N-acetylcysteine dose (a pharmacokinetics review), so the supplement is simply lost. Mitigation: separation of the two by at least two hours.

  • Acetaminophen, also sold as paracetamol (over-the-counter): Monitor. N-acetylcysteine is its antidote and alters its handling; every GlyNAC trial required stopping it. Mitigation: avoidance of routine daily use, with an alternative pain reliever preferred where one is suitable.

  • Other antioxidant supplements (vitamin C, vitamin E, alpha-lipoic acid, astaxanthin): Caution, additive. Stacking them compounds the suppression of the oxidative signalling that drives training adaptation. Mitigation: no stacking, with all of them kept away from the post-exercise window.

  • Blood-pressure-lowering supplements (beetroot or dietary nitrate, magnesium, potassium, garlic extract, omega-3 fatty acids): Caution, additive. Combined lowering can produce dizziness on standing. Mitigation: introduction one at a time, with standing blood pressure logged.

  • Sedating supplements (melatonin, magnesium glycinate, L-Theanine, valerian): Caution, additive. Evening glycine adds to their sleep-promoting and temperature-lowering effect. Mitigation: the other agent is reduced first, and driving is deferred until the response is known.

  • Trace-mineral supplements (zinc, copper, selenium): Monitor. The free thiol group binds metals and can reduce their absorption. Mitigation: minerals taken at least two hours apart from GlyNAC, with zinc and copper rechecked annually.

  • Hormetic interventions (sauna, cold exposure, hypoxic training, hyperbaric oxygen): Caution, blunting. These work through brief oxidative and heat-shock signals that a large antioxidant load may damp. Mitigation: separation by four hours or more; no trial has tested this directly.

Populations who should avoid GlyNAC:

  • Active or progressing malignancy, and cancers treated within the past five years, given the mouse tumour-progression signal
  • Chronic kidney disease stage 4 or 5, meaning estimated filtration below 30 mL/min/1.73 m², or serum creatinine above 1.5 mg/dL
  • Liver disease with transaminases above twice the upper limit of normal, or cirrhosis of Child-Pugh Class B or C (a severity grade based on bilirubin, albumin, clotting and fluid retention)
  • Poorly controlled asthma, meaning forced expiratory volume in one second below 60% of predicted, or any documented acetylcysteine-induced bronchospasm
  • Known hypersensitivity to acetylcysteine in any form
  • Pregnancy and breastfeeding, for which no data at these doses exist
  • Anyone taking clozapine
  • Adults under 40, in whom no trial has found anything to correct

Risk Mitigation Strategies

  • Quarter dose with titration over four weeks: Starting near 25 mg/kg each of glycine and N-acetylcysteine daily and stepping up weekly toward the trial dose limits the nausea, bloating and diarrhoea that drive early discontinuation.

  • Daily amount split across two doses with food: Half with breakfast and half with the evening meal halves the single-sitting powder load, the main driver of gastrointestinal intolerance.

  • Larger share shifted to the evening: Loading glycine toward bedtime converts its sedative and temperature-lowering effect into a benefit rather than daytime drowsiness.

  • Dosing separated from hard training by four hours or more: Keeping thiol antioxidants away from the post-exercise window preserves the reactive-oxygen signalling that drives strength and mitochondrial adaptation.

  • Creatinine and liver transaminases before starting and every three months: This is the exact monitoring the trials used, and it guards the one group the trials never enrolled — people with impaired nitrogen handling.

  • No initiation during active malignancy: Until the mouse tumour-progression signal has a human counterpart, deferred use removes exposure to an unresolved risk.

  • Low test dose first where asthma or atopy is present: A small test dose surfaces acetylcysteine hypersensitivity, including bronchospasm, before a full gram-level exposure.

Therapeutic Protocol

  • Standard regimen: Glycine 1.33 mmol/kg and cysteine 0.81 mmol/kg daily, the cysteine given as N-acetylcysteine — about 100 and 133 mg/kg, a 1:1.3 ratio by weight, roughly 7 g and 9 g for a 70 kg adult, taken together.

  • Popularised by: Rajagopal Sekhar’s Translational Metabolism Unit at Baylor College of Medicine, whose pharmacist-prepared capsule protocol every trial of the combination from that unit has used.

  • Competing lighter approach: The Nestlé trial ran fixed 1:1 doses of 2.4, 4.8 or 7.2 g daily, several-fold lower. It missed its endpoint overall but moved glutathione in the high-oxidative-stress subgroup at the two upper doses.

  • Competing surgical-prevention approach: The Vanderbilt phase 4 protocol uses a flat 200 mg/kg daily of a 1:1 commercial preparation in two divided doses, showing that the 1:1 ratio is also in active clinical use.

  • Split versus single dose: Every protocol divides the day’s amount in two. N-acetylcysteine’s roughly 6-hour half-life and the sheer powder volume both argue against a single sitting.

  • Half-life: Oral N-acetylcysteine has a terminal half-life near 6 hours with about 4–10% bioavailability; glycine clears within hours. Neither accumulates, so daily dosing is continuous rather than loading.

  • Best time of day: Morning and evening with meals. Food blunts nausea, and the evening dose lets glycine’s sleep-promoting effect land usefully.

  • Age: All efficacy data come from adults over 60 or from younger adults with a disease-driven deficit. Trial upper limits reached 80–85 years; above that there are no data.

  • Sex: No trial has been powered for sex differences in dose or response. Dosing is by body weight, which already absorbs much of the average size difference.

  • Baseline biomarkers: Low red-cell glutathione, high oxidative-damage markers, and raised fasting insulin identify who moved most, so these guide whether the full dose is worth its cost and bulk.

  • Pre-existing conditions: Type 2 diabetes and HIV responded at the same dose as healthy aging. Impaired kidney or liver function was excluded everywhere, so no dose there is evidence-based.

  • Genetic variants: GSTM1 and GSTT1 null status, GCLM promoter variants, and MTHFR variants (affecting folate and methyl-group handling, which glycine also feeds) plausibly shift the useful dose. No trial has stratified on any of them.

Discontinuation & Cycling

  • Continuous rather than time-limited: Benefits are maintenance-dependent, not cumulative. Twelve weeks after withdrawal, glutathione, oxidative damage, insulin resistance, strength and cognition had all moved back toward pre-supplement values.

  • Both agents stop together: No protocol tapers one before the other, and no trial has withdrawn glycine and N-acetylcysteine separately, so there is no basis for staggering them.

  • No withdrawal syndrome: Stopping produced loss of accrued benefit, not rebound symptoms. Oxidative-damage markers rose but stayed below the original baseline, hinting at some persistence.

  • No taper needed: Neither compound produces dependence or receptor adaptation, and trials stopped both abruptly without adverse events.

  • Cycling not supported: No loss of response appeared over 24 weeks of continuous use, so the usual reason to cycle is absent, and the withdrawal data show cycling would simply forfeit benefit during the off weeks.

Sourcing and Quality

  • N-acetylcysteine regulatory status: United States regulators disputed its status as a dietary supplement before settling into enforcement discretion, which has left supply inconsistent. Pharmaceutical-grade material carries a European Pharmacopoeia or United States Pharmacopeia monograph.

  • Glycine purity: Pharmaceutical or food grade rather than technical grade is the relevant distinction. Glycine is cheap enough that there is no economic reason to accept an unspecified grade.

  • Third-party testing: NSF International, United States Pharmacopeia or Informed Choice certification verifies identity, dose and absence of heavy metals — the routine gaps in bulk amino-acid supply chains.

  • Form: Powder is the practical choice at these amounts; matching the trial dose in capsules means swallowing dozens daily. Sustained-release or effervescent N-acetylcysteine changes absorption in ways no trial has tested.

  • Freshness and storage: N-acetylcysteine oxidises and yellows with heat and humidity. Modest quantities kept sealed and dry preserve it; darkened or strongly sulfurous material is spoiled.

  • Compounding pharmacies: Every Baylor trial used pharmacist-prepared capsules. A compounding pharmacy remains the closest match to trial material for anyone wanting dose accuracy verified.

Practical Considerations

  • Time to effect: Glutathione and oxidative-damage markers move within two weeks. Physical function, cognition and body composition needed 12–24 weeks in the trials, so a fair trial period is three to six months.

  • Common pitfall — under-dosing: Typical retail products supply 600–1,200 mg of N-acetylcysteine, under a tenth of the trial dose. Taking a standard NAC capsule and expecting trial results is the most frequent mistake.

  • Common pitfall — omitting glycine: N-acetylcysteine alone is the more familiar supplement, but the whole premise is that glycine is independently rate-limiting; leaving it out tests a different intervention.

  • Common pitfall — stopping too early: Gastrointestinal complaints peak in the first weeks at full dose and largely resolve with titration, so abandoning the protocol early is avoidable.

  • Regulatory status: Both are sold as dietary supplements in most markets, with N-acetylcysteine also a prescription medicine for overdose and mucus clearance. Use for longevity is off-label in every jurisdiction.

  • Cost and accessibility: Bulk powder puts a full trial dose in the low tens of dollars monthly, so cost is not a barrier; the bulk and taste of 16 g of powder daily are the real accessibility limit.

  • No payer stake either way: Because the compounds are cheap, self-funded and sold without prescription, neither insurers nor national health systems reimburse them or save money by discouraging them, so guideline formation carries no payer-driven incentive here.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Glycine lowers core temperature by widening skin blood vessels, acting through N-methyl-D-aspartate receptors in the brain’s master clock, which shortens time to sleep. Practical step: a more heavily weighted evening dose, timed 30–60 minutes before bed.

  • Nutrition: Direct and additive on the glycine side. Collagen, gelatin, bone broth and skin-on cuts already supply several grams of glycine daily, so a collagen-heavy diet narrows the gap the supplement fills. Practical step: both doses with food, which reduces nausea.

  • Exercise: Blunting, and the clearest conflict in this review. Thiol antioxidants suppress the reactive-oxygen signalling through which training drives strength and mitochondrial adaptation, shown for N-acetylcysteine after eccentric exercise. Practical step: dosing separated from hard sessions by four or more hours.

  • Stress management: Indirect. No trial has measured cortisol or stress reactivity on the combination, and no mechanism links either amino acid to the stress axis directly. Any effect runs through better sleep and lower inflammatory tone rather than through the stress response itself.

Monitoring Protocol & Defining Success

Baseline work centres on the two safety anchors the trials used — serum creatinine with estimated filtration rate, and liver transaminases — since every study excluded people outside normal range on either, alongside a complete blood count, fasting glucose and insulin, glycated haemoglobin, high-sensitivity C-reactive protein, homocysteine, and a seated blood pressure. Function belongs at the same visit: 4-metre gait speed and handgrip strength, the two endpoints that moved most. Once running, creatinine and transaminases are repeated at 4 and 12 weeks, then every 3–6 months for as long as the supplement continues. Metabolic and inflammatory markers, blood pressure, and the two function measures are worth repeating at 12 and 24 weeks, then every 6–12 months, because 12–24 weeks is when the trials saw function change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine and estimated glomerular filtration rate Creatinine 0.6–1.1 mg/dL; filtration rate above 80 mL/min/1.73 m² Kidney handling of a large nitrogen and sulfate load Estimated glomerular filtration rate (eGFR) is a calculation of kidney filtering capacity. Trials excluded creatinine above 1.5 mg/dL and rechecked every 4 weeks; conventional labs flag only above roughly 1.2–1.3 mg/dL
Alanine aminotransferase and aspartate aminotransferase Both below 25 U/L Liver tolerance of sustained thiol loading Alanine and aspartate aminotransferase (ALT and AST) are enzymes released by stressed liver cells. Conventional upper limits reach 40–55 U/L; trials excluded anything above twice that and rechecked every 4 weeks
Fasting insulin 2–5 µIU/mL The endpoint that moved most in metabolic terms Fasting of 10–12 hours is required; pairing with fasting glucose allows insulin resistance to be derived. Conventional labs accept up to roughly 25 µIU/mL, five times the functional ceiling
Fasting glucose 75–90 mg/dL Tracks the fat-versus-glucose burning shift Fasting of 10–12 hours is required; the morning draw supplies insulin from the same sample. Conventional labs flag only above 99 mg/dL
Glycated haemoglobin 4.8–5.3% Slow-moving confirmation that fasting changes are real Glycated haemoglobin (HbA1c) reflects average blood sugar over roughly three months. No fasting required; meaningless before 12 weeks of use; conventional threshold for concern is 5.7%
High-sensitivity C-reactive protein Below 0.8 mg/L The inflammation claim is the most contested; this is the validated way to test it personally A general marker of body-wide inflammation. The result is uninterpretable during illness or recent injury; conventional low-risk cut-off is 1.0 mg/L
Homocysteine 6–8 µmol/L N-acetylcysteine lowers it; glycine loads the same methyl-group pathway An amino acid linked to vascular and cognitive risk. Fasting and prompt plasma separation are required; conventional labs accept up to 15 µmol/L
Seated systolic blood pressure 105–120 mmHg The one validated clinical surrogate the placebo-controlled trial moved The average of three seated readings after 5 minutes rest, at the same time of day
Whole-blood reduced glutathione, with the reduced-to-oxidised ratio No established target; change from the individual’s own baseline is what to track instead The mechanism’s proximate output, and the marker an independent trial failed to move Sample handling dominates the result; one laboratory throughout and a fasted draw are essential
4-metre gait speed Above 1.0 m/s, and rising from personal baseline Function, not biochemistry, is what the strongest evidence supports Same footwear and corridor each time; the average of two walks is recorded
Handgrip strength Above 27 kg (men) or 16 kg (women), and rising from personal baseline Cheap, reproducible proxy for the strength endpoint the trials used Same dynamometer, dominant and non-dominant arms, seated with the elbow at 90°

Qualitative markers worth tracking alongside the numbers:

  • Sleep onset latency and subjective sleep depth, which glycine plausibly changes within days
  • Daytime energy and the sense of effort during routine stair climbing or walking
  • Cognitive clarity, word-finding and mental stamina in the late afternoon
  • Recovery soreness after resistance training, where blunting rather than improvement is the signal of interest
  • Gastrointestinal comfort, bloating and stool consistency during dose escalation

Emerging Research

  • Randomized trial in Alzheimer’s disease: NCT04740580, a triple-blind trial of 52 amyloid-positive adults comparing GlyNAC with alanine placebo over 24 weeks, with cognition, brain glucose uptake and brain inflammation imaging as primary endpoints. Primary completion reached August 2026.

  • Randomized trial in mild cognitive impairment: NCT03493178, 60 adults aged 55–85 given glycine plus N-acetylcysteine or alanine for 12 weeks, then followed 12 weeks after withdrawal. It is the first controlled test of the cognitive signal seen in the open-label pilots.

  • Phase 4 surgical prevention trial: NCT06083480, 148 knee-replacement patients randomised to GlyNAC 200 mg/kg daily or alanine, with worst pain at six months as the primary endpoint. It is the first trial to carry the combination into a surgical setting.

  • Whether precursor supply is limiting at all: The independent 114-person trial of Lizzo et al., 2022 missed its glutathione endpoint and would weaken the case if replicated. Its post-hoc finding — that only high-oxidative-stress, low-glutathione participants responded — is the specific hypothesis a confirmatory trial should test.

  • Whether the antioxidant load costs training adaptation: Michailidis et al., 2013 showed N-acetylcysteine blunting post-exercise growth signalling at a seventh of the GlyNAC dose. No trial has yet combined GlyNAC with a structured training programme in older adults.

  • Whether restoring glutathione shifts cancer risk either way: A genetic-damage marker fell in the human pilot while antioxidants accelerated tumour progression in tumour-bearing mice (Sayin et al., 2014). These point in opposite directions and no human study has yet measured incidence.

Conclusion

GlyNAC pairs two cheap amino acids to rebuild the body’s own main internal antioxidant, whose supply falls with age. The idea rests on a measured finding rather than an assumption: older adults were shown to make less of it because two building blocks had grown scarce.

What the evidence supports most firmly is physical function — walking speed and grip strength improved in older adults, with walking endurance moving the same way but less firmly, held while the supplement continued, and faded within three months of stopping. Metabolic measures and blood pressure moved in one small controlled trial. Gains in thinking tests, body fat and inflammation rest on studies without a placebo comparison, so their size is uncertain even where their direction is not. Fewer winter respiratory infections are documented for one ingredient alone. Longer life has been shown only in mice.

The evidence base has two weaknesses worth weighing together. Almost every positive human result comes from a single laboratory working with a few dozen people, though its authors report no financial interest; the one independent trial, funded by a company that sells such a product, did not reproduce the central biochemical change except in participants who started with the greatest shortfall. Neither side has been refuted.

The drawbacks are modest and mostly manageable: gastrointestinal upset at gram-level doses, a sedating evening effect, and one genuine tension for anyone training hard, since blunting the same oxidative signals that drive adaptation may cost some of what exercise delivers.

Top - Benefits - Risks - Protocol